MAPT and Parkinson disease: Despite failing clinical and functional endpoints, during TAURIET, semorinemab reported lowered CSF t-tau and p-tau levels and increased tau in plasma, moreover it was influential on other CSF biomarkers like NfL, Ng, S100B, and sTREM1, as presented at International Conference on Alzheimer′s and Parkinson′s Diseases 2021 (unpublished results) [156].